Investors

Watch hVIVO’s July 2025 Capital Markets Day here

hVIVO is a publicly traded company on the London Stock Exchange AIM Market under the symbol HVO

Yamin 'Mo' Khan

CEO at hVIVO

"The utility of our services remains strong, as demonstrated by the recent success of our client's Phase II candidate. Our diversification strategy is already delivering results, and we expect continued momentum across all revenue streams. While macroeconomic and sector-specific headwinds are still affecting contract conversions, we remain confident in the long-term growth trajectory of our services and the overall prospects for hVIVO. I'm encouraged by the strength of our sales pipeline, with several major opportunities that could enhance the growth of our services. We believe that we are well positioned to deliver growth in FY26, and we look forward to keeping shareholders updated on our progress."

See Results Centre

Regulatory News

Investment Case

World Leading Capabilities

hVIVO is an early phase the world leader in using human challenge clinical trials to test infectious and respiratory disease vaccines and treatments.
The Company’s history dates back to 1945 to the Salisbury Common Cold unit, which explored the causes of respiratory disease.
hVIVO conducts its trials in its state-of-the-art quarantine facility in London, which is the largest of its kind worldwide.
hVIVO boasts an industry leading volunteer recruitment database, FluCamp, which has over 370,000 volunteers.

Well-funded to Execute on Strategy

The Company is debt free, pays an annual dividend, and has Cash of £23.3 million as at 30 June 2025
Well-funded to execute on its strategy to build a business with sustainable and diversified revenue streams

Long-term Growth Strategy

hVIVO has a clear long-term growth strategy to ‘Optimise, Scale and Diversify’ its business.
Well-positioned for a return to organic growth in FY26, complemented by small bolt-on acquisitions in hVIVO’s areas of core competence.
Acquisitions of two Clinical Research Units from CRS, and temperature-controlled storage solutions provider Cryostore. CRS is expected to be earnings accretive in 2026.
The Board remains confident in the long-term growth potential of hVIVO, with accelerating growth in the newly added services lines as well as HCTs.

Market Dynamics

Long-term trend of increased adoption of human challenge trials by the global biopharma industry.
Strong sales pipeline with substantial opportunities across the Group.
Aggregate value of customer proposals submitted in H1 2025 has already surpassed FY24 with substantial pipeline of opportunities not yet contracted.

High Barriers to Entry

hVIVO optimises its human challenge models after every trial, ensuring each is robust and can deliver clear insights into the efficacy of new vaccines and antivirals.
The Company has world-leading expertise and experience in delivering highly specialised trials over decades.
hVIVO has built extensive infrastructure to deliver its trials, including a state-of-the-art quarantine clinic in a high-density population.

Trusted Partner

hVIVO is a full-service early phase CRO that delivers its services to seven of the top 10 largest biopharma companies in the world.
The company has a growing list of biotechnology clients that value the quick cost-efficient efficacy data that human challenge trials can provide.
Human challenge trials are increasingly accepted by international regulators, with successful trials often leading to FDA Fast Track or Breakthrough designations.

End-To-End Early Clinical Development Services

hVIVO

Venn Life Sciences

CRS

hLAB

Cryostore™

FluCamp

A full service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

Learn more

Two lab technicians inspecting test tubes

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

Visit Venn Life

CRS is a leading early phase CRO with state-of-the-art research units in Germany, excelling in innovative solutions for early clinical development, from First-in-Human studies to Proof-of-Concept trials in patients.

Visit CRS

hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery & development.

Visit hLAB

Cryostore™ is a dedicated GxP storage facility for biological and clinical materials in secure temperature-controlled conditions offering offsite, ultra-low temperature-controlled conditions for the pharmaceutical, biotechnology and healthcare industries.

Visit Cryostore